An Important New Licensing Agreement Between Vertex Pharmaceuticals and CRISPR Therapeutics

Vertex Pharmaceuticals and Crispr Therapeutics Agreement Aims at Accelerating Vertex's Hypo immune Cell Therapies for Type 1 Diabetes
Vertex Pharmaceuticals (VRTX) and CRISPR Therapeutics (CRSP) announced that they have entered into a new non-exclusive licensing agreement for the use of CRISPR Therapeutics’ gene editing . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.